Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer

British Journal of Cancer

Volumn 113, Issue 3, 2015, Pages 414-424

  Hsu, K F ^a   Shen, M R ^a   Huang, Y F ^a   Cheng, Y M ^a   Lin, S H ^a   Chow, N H ^a   Cheng, S W ^a   Chou, C Y ^a   Ho, C L ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; COPPER; HISTIDINE; INSULIN LIKE GROWTH FACTOR 2 MRNA BINDING PROTEIN; LENTIVIRUS VECTOR; LIN 28 HOMOLOG B; MESSENGER RNA; PACLITAXEL; PLATINUM DERIVATIVE; PUROMYCIN; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG; IMP3 PROTEIN, HUMAN; LIN28B PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL ADHESION; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL MIGRATION ASSAY; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC RISK; HUMAN; HUMAN CELL; IC50; IMMUNOHISTOCHEMISTRY; MOLECULAR WEIGHT; OUTCOME ASSESSMENT; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING; AGED; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RNA-BINDING PROTEINS; SURVIVAL RATE; UP-REGULATION;

EID: 84938417711     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.254     Document Type: Article

References (50)

1. Anglesio MS, Wiegand KC, Melnyk N, Chow C, Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR, Shumansky K, Shah SP, Kalloger SE, Huntsman DG (2013) Type-specific cell line models for type-specific ovarian cancer research. PLoS One 8: e72162.
2. Bashirullah A, Cooperstock RL, Lipshitz HD (1998) RNA localization in development. Annu Rev Biochem 67: 335-394.
3. Cheng SW, Tsai HW, Lin YJ, Cheng PN, Chang YC, Yen CJ, Huang HP, Chang TT, Lee CT, Chao A, Chou CY, Chan SH, Chow NH, Ho CL (2013) Lin28B is an oncofetal circulating cancer stem cell marker associated with recurrence of hepatocellular carcinoma. PLoS One 8: e80053.
4. Chen HH, Yan JJ, Chen WC, Kuo MT, Lai YH, Lai WW, Liu HS, Su WC (2012) Predictive and prognostic value of human copper transporter 1 (hCtr1) in patients with stage III non-small-cell lung cancer receiving first-line platinum-based doublet chemotherapy. Lung Cancer 75: 228-324.
5. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4: 2126.
6. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
7. Findeis-Hosey JJ, Xu H (2011) The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 42: 303-314.
8. Grieco A, Rzeczkowska P, Alm C, Palmert MR (2013) Investigation of peripubertal expression of Lin28a and Lin28b in C57BL/6 female mice. Mol Cell Endocrinol 365: 241-248.
9. Gu L, Shigemasa K, Ohama K (2004) Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 24: 671-678.
10. Guo Y, Chen Y, Ito H, Watanabe A, Ge X, Kodama T, Aburatani H (2006) Identification and characterization of lin-28 homolog B (LIN28B) in human hepatocellular carcinoma. Gene 384: 51-61.
11. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535.
12. Hamano R, Miyata H, Yamasaki M, Sugimura K, Tanaka K, Kurokawa Y, Nakajima K, Takiguchi S, Fujiwara Y, Mori M, Doki Y (2012) High expression of Lin28 is associated with tumor aggressiveness and poor prognosis of patients in oesophagus cancer. Br J Cancer 106: 1415-1423.
13. Heitz F, Harter P, Barinoff J, Beutel B, Kannisto P, Grabowski JP, Heitz J, Kurzeder C, du Bois A (2012) Bevacizumab in the treatment of ovarian cancer. Adv Ther 29: 723-735.
14. Helland Å, Anglesio MS, George J, Cowin PA, Johnstone CN, House CM, Sheppard KE, Etemadmoghadam D, Melnyk N, Rustgi AK, Phillips WA, Johnsen H, Birrer MJ. Australian Ovarian Cancer Study GroupPearson RB, Børresen-Dale AL, Huntsman DG, de Fazio A, Creighton CJ, Smyth GK, Bowtell DD (2011) Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 6: e18064.
15. Hsu CC, Chiang CW, Cheng HC, Chang WT, Chou CY, Tsai HW, Lee CT, Wu ZH, Lee TY, Chao A, Chow NH, Ho CL (2011) Identifying LRRC16B as an oncofetal gene with transforming enhancing capability using a combined bioinformatics and experimental approach. Oncogene 30: 654-667.
16. Holzer AK, Manorek GH, Howell SB (2006) Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol 70: 1390-1394.
17. Ip V, Liu JJ, McKeage MJ (2013) Evaluation of effects of copper histidine on copper transporter 1-mediated accumulation of platinum and oxaliplatin-induced neurotoxicity in vitro and in vivo. Clin Exp Pharmacol Physiol 40: 371-378.
18. Ishida S, Lee J, Thiele DJ, Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99: 14298-14302.
19. Ishida S, McCormick F, Smith-McCune K, Hanahan D (2010) Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 17: 574-583.
20. Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, Hsu HC (2008) RNA-binding protein insulin like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology 48: 1118-1127.
21. Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7: 556-564.
22. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K. Japanese Gynecologic Oncology Group (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374: 1331-1338.
23. King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK (2011) LIN28B promotes colon cancer progression and metastasis. Cancer Res 71: 4260-4268.
24. Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, Lee CH, Huntsman D, Gilks CB (2009) IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol 22: 469-475.
25. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39: 673-677.
26. Kuo MT, Chen HH, Song IS, Savaraj N, Ishikawa T (2007) The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 26: 71-83.
27. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK, Ahmed N (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem 112: 2850-2864.
28. Liao B, Hu Y, Herrick DJ, Brewer G (2005) The RNAbinding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280: 18517-18524.
29. Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S (2012) Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 48: 3405-3413.
30. Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Zhang K, Conner M, Landen CN (2012) Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 33: 2119-2125.
31. Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H (2009) Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. Eur J Cancer 45: 2212-2218.
32. Mayr F, Heinemann U (2013) Mechanisms of Lin28-mediated miRNA and mRNA regulation-a structural and functional perspective. Int J Mol Sci 14: 16532-16553.
33. Nielsen FC, Nielsen J, Christiansen J (2001) A family of IGF-II mRNA binding proteins (IMP) involved in RNA trafficking. Scand J Clin Lab Invest Suppl 234: 93-99.
34. Nielsen FC, Nielsen J, Kristensen MA, Koch G, Christiansen J (2002) Cytoplasmic trafficking of IGF-II mRNA-binding protein by conserved KH domains. J Cell Sci 115: 2087-2097.
35. Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19: 1262-1270.
36. Peng S, Maihle NJ, Huang Y (2010) Pluripotency factors Lin28 and Oct4 identify a subpopulation of stem cell-like cells in ovarian cancer. Oncogene 29: 2153-2159.
37. Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM (2010) Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 28: 154-159.
38. Polesskaya A, Cuvellier S, Naguibneva I, Duquet A, Moss EG, Harel-Bellan A (2007) Lin-28 binds IGF-2 mRNA and participates in skeletal myogenesis by increasing translation efficiency. Genes Dev 21: 1125-1138.
39. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G (2000) The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906.
40. Sarkar B, Lingertat-Walsh K, Clarke JTR (1993) Copper-histidine therapy for Menkes disease. J Pediatr 123: 828-830.
41. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN (2012) Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res 18: 869-881.
42. Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25: 1456-1468.
43. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, O'Sullivan M, Lu J, Phillips LA, Lockhart VL, Shah SP, Tanwar PS, Mermel CH, Beroukhim R, Azam M, Teixeira J, Meyerson M, Hughes TP, Llovet JM, Radich J, Mullighan CG, Golub TR, Sorensen PH, Daley GQ (2009) Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet 41: 843-848.
44. Viswanathan SR, Daley GQ (2010) Lin28: A microRNA regulator with a macro role. Cell 140: 445-449.
45. Xue D, Peng Y, Wang F, Allan RW, Cao D (2011) RNA-binding protein LIN28 is a sensitive marker of ovarian primitive germ cell tumours. Histopathology 59: 452-459.
46. Yaniv K, Yisraeli JK (2002) The involvement of a conserved family of RNA binding proteins in embryonic development and carcinogenesis. Gene 287: 49-54.
47. Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K (2005) KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29: 188-195.
48. Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16: 1711-1719.
49. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin, Thomson JA (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
50. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z (2008) The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32: 304-315.